Microvascular disease is damage to the smallest blood vessels in your body, the tiny arterioles, capillaries, and venules that deliver oxygen and nutrients directly to your tissues. Unlike the blockages in large arteries that cause most heart attacks and strokes, microvascular disease affects vessels so small they don’t show up on a standard angiogram. This makes it harder to detect, often misdiagnosed, and historically undertreated. It can affect the heart, brain, kidneys, eyes, and nerves, sometimes all at once.
How Small Vessels Differ From Large Ones
Your cardiovascular system has two tiers. Large vessels (macrovessels) are the highways that carry blood to your organs. Small vessels (microvessels) are the local roads that distribute blood within those organs, regulate blood pressure, and control nutrient delivery at the cellular level. They have different architecture and different cellular components, which means they’re vulnerable to different kinds of damage.
In microvascular disease, the inner lining of these tiny vessels (the endothelium) becomes dysfunctional. Healthy endothelial cells produce nitric oxide, a chemical that relaxes vessel walls and keeps blood flowing smoothly. When those cells are damaged, nitric oxide drops, the vessels can’t dilate properly, and resistance to blood flow increases. Over time, the vessel walls stiffen with excess collagen, the channels narrow, and some vessels disappear entirely, a process called vascular rarefaction. The result is that organs don’t get enough blood, even though no large artery is blocked.
Coronary Microvascular Disease
The heart is where microvascular disease gets the most clinical attention, largely because it causes chest pain that looks like a heart attack but doesn’t match what doctors expect to find. About 50% of patients who have chest pain with objective evidence of reduced blood flow to the heart turn out to have no significant blockage in their major coronary arteries. Many of these patients have coronary microvascular dysfunction (CMD), where the tiny vessels feeding the heart muscle can’t supply enough blood during exertion or stress.
This condition has a formal name: INOCA, or ischemia with non-obstructive coronary arteries. For years, patients with INOCA, the majority of them women, were told their hearts were fine and sent home. They weren’t fine. Studies show that a majority of women with non-obstructive disease continue to have chest pain at one and five years. These patients report greater physical limitations, more frequent angina episodes, and a reduced quality of life compared to people with stable coronary artery disease or even those recovering from a heart attack. INOCA is also associated with higher rates of anxiety and depression.
CMD prevalence ranges between 34 and 66% in women and 14 to 60% in men among patients with chest pain and clean-looking angiograms. The gap is striking. Traditional cardiovascular risk factors like diabetes and high cholesterol predict microvascular problems in men but don’t seem to explain the condition as well in women, suggesting that hormonal and neurological factors play a distinct role in female patients. Up to 75 to 81% of patients hospitalized with a type of heart failure called HFpEF (where the heart pumps normally but can’t relax properly) also have CMD without any large-vessel blockage.
Microvascular Disease in the Brain
In the brain, microvascular disease is often called cerebral small vessel disease. It shows up on MRI scans as white matter hyperintensities, bright spots that indicate damage to the brain’s wiring. A 14-year follow-up study found that higher volumes of these white matter changes were independently associated with dementia, with a 31% increase in risk per standard deviation of additional damage. The presence of tiny new lesions on specialized brain imaging doubled the risk of dementia over the study period.
Cerebral small vessel disease doesn’t always announce itself with dramatic symptoms. It can progress silently for years, contributing to gradual cognitive decline, problems with walking and balance, and mood changes. It is the leading cause of vascular dementia and a major contributor to mixed dementia, where vascular damage and Alzheimer’s disease overlap.
The Diabetic Triad: Eyes, Kidneys, and Nerves
Diabetes is the most well-understood driver of microvascular disease, and the damage follows a recognizable pattern across three organ systems.
Eyes (Diabetic Retinopathy)
Chronic high blood sugar thickens the basement membranes of tiny retinal blood vessels and makes them more permeable. Microaneurysms form. Blood clots inside these damaged vessels, cutting off oxygen to patches of the retina. The eye responds by growing new blood vessels, but these replacement vessels are fragile and prone to rupturing, causing bleeds inside the eye. Fluid also accumulates in the central retina (macular edema) because the retina has no lymphatic drainage to clear it. This is why diabetic retinopathy remains a leading cause of blindness.
Kidneys (Diabetic Nephropathy)
The kidneys’ filtering units are dense networks of microvessels. High glucose levels cause the vessel walls to thicken, tissue between the vessels to scar (fibrosis), and the filtering mechanism to malfunction. Early on, the kidneys actually overfilter, pushing too much through damaged filters. Over time, function progressively declines. This damage is the leading cause of kidney failure requiring dialysis.
Nerves (Diabetic Neuropathy)
The tiny blood vessels that supply peripheral nerves are also targets. When those vessels are damaged, the nerves they feed begin to die, causing numbness, tingling, and pain, usually starting in the feet. The combination of nerve damage, impaired blood flow, and increased infection risk is the primary driver behind diabetic foot amputations.
The underlying mechanism across all three is the same: sustained high blood sugar causes direct endothelial damage, triggers oxidative stress, and generates toxic byproducts that alter blood flow, increase vessel permeability, and deposit abnormal proteins outside the vessels.
What Drives Microvascular Damage
Beyond diabetes, several conditions accelerate microvascular disease. High blood pressure is one of the most potent. In hypertensive patients, angiotensin II (a hormone that raises blood pressure) also increases production of harmful oxygen molecules called reactive oxygen species. These molecules neutralize nitric oxide before it can do its job, making vessels unable to relax. At the same time, oxidative stress triggers inflammatory pathways that further damage the vessel lining. The vessels respond by producing excess collagen, becoming stiffer and more fibrotic. Notably, microvascular dysfunction in hypertensive patients develops even before the heart shows signs of thickening, meaning the small vessels are an early target.
Other established risk factors include obesity, metabolic syndrome, smoking, chronic inflammation, and aging itself. In coronary microvascular disease specifically, the damaged endothelial cells can transform into a different cell type that produces scar tissue, a process called endothelial-mesenchymal transition. These transformed cells lose their ability to maintain vessel integrity, further accelerating fibrosis and vessel loss.
How Microvascular Disease Is Diagnosed
Standard heart catheterization, which looks for blockages in large arteries, will miss microvascular disease entirely. That’s why specialized testing is needed.
The reference standard is coronary reactivity testing (CRT), an invasive procedure performed in the catheterization lab. Doctors thread a guidewire with pressure and flow sensors into a coronary artery, then administer drugs that should cause the vessels to dilate. By measuring how much blood flow increases, they can calculate coronary flow reserve (CFR), the ratio of maximum blood flow to resting flow. A CFR below 2.0 to 2.5 indicates microvascular dysfunction. They can also calculate the index of microcirculatory resistance (IMR), where a value of 25 or above signals abnormal microvascular resistance.
Doctors can also test whether the endothelium itself is functioning by infusing acetylcholine, a chemical that triggers healthy endothelial cells to dilate vessels. If blood flow fails to increase by at least 50% in response, endothelial-dependent microvascular disease is present. Higher doses of acetylcholine can also provoke vessel spasms, helping diagnose microvascular spasm, a condition where tiny vessels clamp down unpredictably.
For non-invasive screening, cardiac PET imaging and stress cardiac MRI both carry favorable recommendations from the European Society of Cardiology and the American Heart Association. These can estimate coronary flow reserve without a catheter, making them useful as a first step before deciding whether invasive testing is warranted.
Living With Microvascular Disease
Management focuses on controlling the conditions that drive microvascular damage: keeping blood pressure in range, managing blood sugar tightly in diabetes, addressing cholesterol, quitting smoking, and maintaining a healthy weight. For coronary microvascular disease specifically, medications that improve vessel relaxation, reduce spasm, and lower inflammation form the core of treatment, though the optimal combination varies from patient to patient.
The most important shift in recent years has been recognition. For decades, patients (especially women) with chest pain and clean angiograms were dismissed. Current guidelines from both American and European cardiology societies now give favorable recommendations for invasive coronary function testing in patients with INOCA, acknowledging that non-obstructive disease is real, measurable, and treatable. If you’ve been told your arteries look fine but you’re still having symptoms, asking about microvascular testing is a reasonable next step.